Drug Approval | May 13, 2024
Zydus receives final approval from USFDA for Dexamethasone Tablets
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company is committed to address this observation comprehensively within stipulated time
The product is used to treat amyotrophic lateral sclerosis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
With this, for all our USFDA facilities, EIRs are in place
Subscribe To Our Newsletter & Stay Updated
